2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

  • Alexander R Lyon
  • , Teresa López-Fernández
  • , Liam S Couch
  • , Riccardo Asteggiano
  • , Marianne C Aznar
  • , Jutta Bergler-Klein
  • , Giuseppe Boriani
  • , Daniela Cardinale
  • , Raul Cordoba
  • , Bernard Cosyns
  • , David J Cutter
  • , Evandro de Azambuja
  • , Rudolf A de Boer
  • , Susan F Dent
  • , Dimitrios Farmakis
  • , Sofie A Gevaert
  • , Diana A Gorog
  • , Joerg Herrmann
  • , Daniel Lenihan
  • , Javid Moslehi
  • Brenda Moura, Sonja S Salinger, Richard Stephens, Thomas M Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G Tocchetti, Peter van der Meer, Helena J H van der Pal, Patrizio Lancellotti, Franck Thuny, Magdy Abdelhamid, Victor Aboyans, Berthe Aleman, Joachim Alexandre, Ana Barac, Michael A Borger, Ruben Casado-Arroyo, Jennifer Cautela, Jolanta Čelutkienė, Maja Cikes, Alain Cohen-Solal, Kreena Dhiman, Stéphane Ederhy, Thor Edvardsen, Laurent Fauchier, Michael Fradley, Tiny Jaarsma, Dipak Kotecha,

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4229-4361
Number of pages133
JournalEuropean heart journal
Volume43
Issue number41
DOIs
Publication statusPublished - 1 Nov 2022
Externally publishedYes

Keywords

  • Amyloid light-chain cardiac amyloidosis
  • Androgen deprivation therapy
  • Anthracycline
  • Arrhythmias
  • Atrial fibrillation
  • Biomarkers
  • Cancer
  • Cancer survivors
  • Carcinoid syndrome
  • Cardiac magnetic resonance
  • Cardiac tumour
  • Cardio-oncology
  • Cardiotoxicity
  • Chemotherapy
  • Coronary artery disease
  • Echocardiography
  • Fluoropyrimidine
  • Guidelines
  • Haematopoietic stem cell transplantation
  • Heart failure
  • Hormone therapy
  • Hypertension
  • Immunotherapy
  • Ischaemic heart disease
  • Myocarditis
  • Pericardial disease
  • Proteasome inhibitors
  • Pulmonary hypertension
  • QTc prolongation
  • Radiotherapy
  • Risk stratification
  • Strain
  • Thrombosis
  • Trastuzumab
  • Valvular heart disease
  • Vascular endothelial growth factor inhibitors (VEGFi)
  • Venous thromboembolism

Cite this